ECSP11010847A - Métodos para tratar la talasemia - Google Patents
Métodos para tratar la talasemiaInfo
- Publication number
- ECSP11010847A ECSP11010847A EC2011010847A ECSP11010847A ECSP11010847A EC SP11010847 A ECSP11010847 A EC SP11010847A EC 2011010847 A EC2011010847 A EC 2011010847A EC SP11010847 A ECSP11010847 A EC SP11010847A EC SP11010847 A ECSP11010847 A EC SP11010847A
- Authority
- EC
- Ecuador
- Prior art keywords
- talasemia
- treat
- methods
- thalassemia
- effective amount
- Prior art date
Links
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 101150009057 JAK2 gene Proteins 0.000 abstract 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 abstract 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 abstract 1
- 208000002903 Thalassemia Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente invención se proporciona un método para tratar, mejorar, o retrasar al menos un síntoma de un trastorno sanguíneo genético, por ejemplo, anemia drepanocítica o talasemia, en un paciente que lo necesite, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2. También se proporciona en parte un método para reducir un bazo dilatado en un paciente que padece talasemia, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8623308P | 2008-08-05 | 2008-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11010847A true ECSP11010847A (es) | 2011-07-29 |
Family
ID=41581108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011010847A ECSP11010847A (es) | 2008-08-05 | 2011-02-28 | Métodos para tratar la talasemia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110269721A1 (es) |
| EP (1) | EP2355827A2 (es) |
| JP (1) | JP2011530517A (es) |
| KR (1) | KR20110053347A (es) |
| CN (1) | CN102112131A (es) |
| AU (1) | AU2009279825A1 (es) |
| BR (1) | BRPI0917575A2 (es) |
| CA (1) | CA2732791A1 (es) |
| CL (1) | CL2011000242A1 (es) |
| CO (1) | CO6351728A2 (es) |
| CR (1) | CR20110115A (es) |
| DO (1) | DOP2011000044A (es) |
| EC (1) | ECSP11010847A (es) |
| IL (1) | IL211061A0 (es) |
| MA (1) | MA32611B1 (es) |
| MX (1) | MX2011001426A (es) |
| NI (1) | NI201100031A (es) |
| RU (1) | RU2011108563A (es) |
| SV (1) | SV2011003823A (es) |
| WO (1) | WO2010017122A2 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2543376A1 (en) | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| AU2005276974B2 (en) | 2004-08-25 | 2012-08-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| KR101737753B1 (ko) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CA2819560A1 (en) * | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
| PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| CN103664799A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| RU2693480C2 (ru) * | 2013-03-14 | 2019-07-03 | Толеро Фармасьютикалз, Инк. | Ингибиторы jak2 и alk2 и способы их использования |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
| KR102571679B1 (ko) * | 2016-04-15 | 2023-08-29 | 에피자임, 인코포레이티드 | Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물 |
| WO2018183923A1 (en) * | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| CN118021814A (zh) | 2017-04-21 | 2024-05-14 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| US20210260040A1 (en) * | 2017-10-18 | 2021-08-26 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in treating or preventing blood disorders |
| JP2021500327A (ja) * | 2017-10-18 | 2021-01-07 | エピザイム，インコーポレイティド | 免疫療法にｅｈｍｔ２阻害剤を使用する方法 |
| EP3773591A4 (en) | 2018-04-05 | 2021-12-22 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL KINASE INHIBITORS AND THEIR USE |
| CN117959303A (zh) | 2018-04-13 | 2024-05-03 | 住友制药肿瘤公司 | 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂 |
| CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
| CN110305140B (zh) | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| CN112778282B (zh) * | 2021-01-06 | 2022-07-22 | 温州医科大学 | 一种嘧啶类小分子化合物及其应用 |
| EP4611753A1 (en) | 2022-10-31 | 2025-09-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ567851A (en) * | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
-
2009
- 2009-08-03 CA CA2732791A patent/CA2732791A1/en not_active Abandoned
- 2009-08-03 RU RU2011108563/15A patent/RU2011108563A/ru not_active Application Discontinuation
- 2009-08-03 WO PCT/US2009/052544 patent/WO2010017122A2/en not_active Ceased
- 2009-08-03 KR KR1020117005224A patent/KR20110053347A/ko not_active Withdrawn
- 2009-08-03 US US13/057,133 patent/US20110269721A1/en not_active Abandoned
- 2009-08-03 CN CN2009801303954A patent/CN102112131A/zh active Pending
- 2009-08-03 MX MX2011001426A patent/MX2011001426A/es not_active Application Discontinuation
- 2009-08-03 AU AU2009279825A patent/AU2009279825A1/en not_active Abandoned
- 2009-08-03 JP JP2011522136A patent/JP2011530517A/ja active Pending
- 2009-08-03 BR BRPI0917575A patent/BRPI0917575A2/pt not_active IP Right Cessation
- 2009-08-03 EP EP09741504A patent/EP2355827A2/en not_active Withdrawn
-
2011
- 2011-02-01 SV SV2011003823A patent/SV2011003823A/es not_active Application Discontinuation
- 2011-02-02 NI NI201100031A patent/NI201100031A/es unknown
- 2011-02-03 DO DO2011000044A patent/DOP2011000044A/es unknown
- 2011-02-03 IL IL211061A patent/IL211061A0/en unknown
- 2011-02-04 CL CL2011000242A patent/CL2011000242A1/es unknown
- 2011-02-28 EC EC2011010847A patent/ECSP11010847A/es unknown
- 2011-03-02 CR CR20110115A patent/CR20110115A/es not_active Application Discontinuation
- 2011-03-04 CO CO11026653A patent/CO6351728A2/es not_active Application Discontinuation
- 2011-03-04 MA MA33672A patent/MA32611B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011530517A (ja) | 2011-12-22 |
| CO6351728A2 (es) | 2011-12-20 |
| MA32611B1 (fr) | 2011-09-01 |
| EP2355827A2 (en) | 2011-08-17 |
| WO2010017122A3 (en) | 2010-04-08 |
| SV2011003823A (es) | 2011-08-15 |
| BRPI0917575A2 (pt) | 2019-09-24 |
| CL2011000242A1 (es) | 2011-04-08 |
| MX2011001426A (es) | 2011-03-21 |
| WO2010017122A2 (en) | 2010-02-11 |
| CN102112131A (zh) | 2011-06-29 |
| DOP2011000044A (es) | 2011-04-30 |
| CR20110115A (es) | 2011-06-03 |
| CA2732791A1 (en) | 2010-02-11 |
| US20110269721A1 (en) | 2011-11-03 |
| IL211061A0 (en) | 2011-04-28 |
| RU2011108563A (ru) | 2012-09-10 |
| AU2009279825A1 (en) | 2010-02-11 |
| NI201100031A (es) | 2011-09-26 |
| KR20110053347A (ko) | 2011-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6351728A2 (es) | Metodos para tratar la talasemia | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| CL2020001019A1 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos. | |
| EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
| WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
| WO2010009342A3 (en) | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | |
| WO2012158957A3 (en) | Kinase modulation and indications therefor | |
| EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
| EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
| BR112014002141A2 (pt) | crizotinib para uso no tratamento de câncer | |
| WO2008063157A3 (en) | A nanoparticle-based anticoagulant | |
| WO2007098099A3 (en) | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения | |
| WO2012170945A3 (en) | Methods for modulating kallikrein (klkb1) expression | |
| EA201001749A1 (ru) | Способ лечения недифференцированного артрита | |
| AU2010279892A8 (en) | Humanized anti-amyloid-b oligomer antibody | |
| WO2013028070A3 (en) | Compounds for use in boosting coagulation | |
| WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
| TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| UY33332A (es) | Compuestos de triazol como inhibidores de ksp | |
| WO2014043223A8 (en) | Irhom2 inhibition for the treatment of complement mediated disorders | |
| WO2010075314A3 (en) | Topical formulations of flap inhibitors for the treatment of dermatological conditions |